Chemotherapy has been known to cause severe side effects, including fatigue. While the mechanisms for chemotherapy induced fatigue (CIF) are likely to be multi-factorial in origin, it is thought that inflammation and anemia may play a role. The purpose of this study was to examine the effect of chemotherapy on fatigue in mice, and further, to begin to determine if inflammation and anemia may contribute to this response. For experiment 1, C57BL/6 mice were assigned to: vehicle (PBS), low (20 mg/kg), medium (40 mg/kg), or high (60 mg/kg) doses of 5-fluorouracil (5-FU). Voluntary physical activity (PA) was measured throughout the treatment period (day 1-5) as well as during the recovery period (day 6-14). In experiment 2, we examined the effects of 5-FU (60 mg/kg) on the inflammatory mediator MCP-1 and on markers of anemia (RBC, Hct and Hb). Finally, using MCP-1 À/À mice we examined the role of MCP-1 on CIF (experiment 3). 5-FU reduced voluntary PA in a dose response manner (p < 0.05). Plasma MCP-1 was increased following 5-FU treatment on both days 5 (p = 0.10) and 14 (p < 0.05). In addition, RBCs, Hct and Hb were reduced with 5-FU on days 5 and 14 (p < 0.05). Both C57BL/6 and MCP-1 À/À mice saw similar decrements in PA through the duration of the treatment period (days 1-5), however the MCP-1 À/À mice recovered much earlier than wildtype mice. This study provides evidence of the dose response effect of a standard chemotherapy agent on fatigue and demonstrates a potential role of MCP-1 and presumably inflammation, and anemia.
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Introduction
The most commonly reported symptom among cancer sufferers is fatigue. The National Comprehensive Cancer Network (NCCN) has defined cancer related fatigue (CRF) as an ''unusual, persistent, subjective sense of tiredness related to cancer or cancer treatment that interferes with usual functioning.'' CRF is thought to affect more than 70% of cancer patients with some assessments as high as 80-99% for those who are currently undergoing treatment (Jean-Pierre et al., 2007) . This type of fatigue may drastically affect quality of life (QOL) (Curt, 2000; Mock, 2001 ), self-care capabilities (Jean-Pierre et al., 2007; Macquart-Moulin et al., 1999) , desire to continue treatment (Macquart-Moulin et al., 1999) and consequently, overall survival. Even with the prevalence of CRF so high, little research has been done to elucidate the underlying mechanisms. This is not surprising given the complexity of this phenomenon; both cancer itself and cancer treatments like chemotherapy can cause fatigue but the relative contribution of each is currently unknown.
While it is generally well accepted that chemotherapy can contribute to fatigue in cancer patients, the mechanisms for this have not yet been fully elucidated (Kornblith et al., 2011) . However, several hypotheses have been postulated and include: central serotonin dysregulation, HPA axis dysfunction, circadian disruption, depression, anemia, and central and peripheral inflammation (Ryan et al., 2007; Jager et al., 2008; Morrow et al., 2002; Dantzer et al., 2012) . Arguably, the strongest of these are inflammation and anemia. Indeed, fatigue in cancer patients has been associated with an increase in inflammatory proteins, specifically in those patients who have undergone chemotherapy (Pusztai and Mendoza, 2004; Dantzer et al., 2012) . For example, Wang et al. (2010) found that IL-6 and TNF-aR1 were positively associated with fatigue in patients completing concurrent chemoradiation therapy. This same association was observed for the Nf-jB pathway in breast cancer survivors (Bower et al., 2011) . In addition, cancer patients suffering from fatigue have increased plasma levels of IL-6 and in some cases TNF-a (Jager et al., 2008) . Inflammatory cytokines have also been linked to anemia (Jager et al., 2008) ; inflammation has been reported to increase apoptosis in erythrocytes and reduce erythrocyte production (Jager et al., 2008; Birgegård et al., 2005) .
